NeuroOne Successfully Implants Spinal Cord Stimulation Device in Animal Model

NeuroOne (Nasdaq: NMTC) has successfully completed an initial animal implant of its novel thin film paddle leads for spinal cord stimulation.

The company’s devices are intended for the treatment of patients with chronic back pain due to multiple failed back surgery syndrome, intractable low back and leg pain.

Highlights

• NeuroOne’s study evaluated the feasibility of implanting a variety of sizes and shapes of ultra-thin paddle leads in a sheep model.
• A mini laminectomy surgical approach was used to gain access to the epidural space for device placement and devices were easily advanced to the target location in under one minute.
• NeuroOne’s lead fit comfortably in the epidural space and the veterinary surgeon reported no concerns regarding the placement of the lead.
• The study results demonstrated feasibility for placement of a thin film paddle lead intended to treat chronic back pain due to multiple failed back surgeries.
• NeuroOne is also developing a percutaneous (through a needle) paddle lead placement system which would eliminate the need for an incision in the patient’s back. Preliminary testing for this approach has also been successfully completed.

About NeuroOne

NeuroOne Medical Technologies Corporation is developing minimally invasive solutions for EEG recording, brain stimulation and ablation for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors and chronic pain due to failed back surgeries and other related neurological disorders. NeuroOne may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence.